

## Special Issue

# Vaccines against SARS-CoV-2 Variants

### Message from the Guest Editor

During the two-year SARS-CoV-2 epidemic, several variants of concern (VOC) have evolved. The effectiveness of the COVID-19 vaccines declined significantly against VOCs. Additionally, vaccine-induced protection was reported to wane with time. Thus, vaccines that could protect people against SARS-CoV-2 variants and potential newly emerged coronaviruses are urgently needed. As such, the following questions have arisen: are there any potential techniques to be used for developing such kind of vaccines? What is the key to developing a vaccine against variants? What are the difficulties of the technique? How can we assess the effectiveness? What is the prospect of a universal coronavirus vaccine? What is the development status of universal vaccines against other pathogens? This Special issue will provide a platform for scholars to communicate their professional views and study results to boost universal coronavirus vaccines development.

### Guest Editor

Dr. Dingmei Zhang

Department of Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou 510080, China

### Deadline for manuscript submissions

closed (1 July 2023)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/116888](https://mdpi.com/si/116888)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).